Date Title Document
Date 10/09/25 Title Bausch Health Announces Results of Special Meeting of Shareholders Document pdf
Date 09/30/25 Title Bausch Health’s Aesthetic Business, Solta Medical, Brings Non-Invasive Aesthetic Innovations to National TV Document pdf
Date 09/30/25 Title Bausch Health to Announce Third Quarter 2025 Results on October 29 Document pdf
Date 09/29/25 Title Bausch Health’s OraPharma Introduces “OraTalks,” a New Podcast Bringing Bold Conversations to Dentistry Document pdf
Date 09/11/25 Title Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio Document pdf
Date 09/05/25 Title Bausch Health’s Aesthetic Business, Solta Medical, Surpasses Milestone of 5 Million Skin Tightening Treatments with Thermage® Non-Surgical System Document pdf
Date 09/01/25 Title Bausch Health Launches YUN Probiotherapy™ ACN Skincare Line in Poland Document pdf
Date 09/01/25 Title Bausch Health Launches YUN Probiotherapy™ ACN Skincare Line in Poland (Polish) Document pdf
Date 08/26/25 Title Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025 Document pdf
Date 08/21/25 Title Bausch Health, Canada Inc. treatment for acne vulgaris, PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide gel), now available through public drug plans of Quebec and Saskatchewan Document pdf
Date 08/21/25 Title Bausch Health, Canada Inc. treatment for acne vulgaris, PrCABTREOMC (clindamycin phosphate, adapalene and benzoyl peroxide gel), now available through public drug plans of Quebec and Saskatchewan (French) Document pdf
Date 08/15/25 Title Bausch Health Announces Increase in Shareholding by its Chairperson of the Board and Board Changes Document pdf
Date 08/07/25 Title Bausch Health Announces 2025 Gastrointestinal Health Scholars Program Winners Document pdf
Date 07/30/25 Title Bausch Health Announces Second Quarter 2025 Results Document pdf
Date 07/29/25 Title Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease Document pdf
Date 07/28/25 Title Bausch Health to Reduce Debt by Approximately $900 Million Using Cash On Hand Document pdf
Date 07/24/25 Title Bausch Health Announces the Appointment of Two New Members to Its Board of Directors Document pdf
Date 07/10/25 Title Bausch Health Appoints New Chief Accounting Officer Document pdf
Date 07/09/25 Title Bausch Health, Canada Inc. treatment for acne vulgaris, PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide gel), now available through public drug plans of Ontario, Nova Scotia and two federal programs Document pdf
Date 07/09/25 Title Bausch Health, Canada Inc. treatment for acne vulgaris, PrCABTREOMC (clindamycin phosphate, adapalene and benzoyl peroxide gel), now available through public drug plans of Ontario, Nova Scotia and two federal programs (French) Document pdf
Date 07/07/25 Title Bausch Health’s Gastroenterology Business, Salix Pharmaceuticals, Launches Fresh “I Wish I Knew” Campaign to Educate People About Xifaxan® (rifaximin) for Adults at Risk of Overt Hepatic Encephalopathy Recurrence Document pdf
Date 07/02/25 Title Bausch Health to Announce Second Quarter 2025 Results on July 30 Document pdf
Date 06/23/25 Title Bausch Health Partners with YUN to Bring Pioneering Microbiome Skincare to Poland (English) Document pdf
Date 06/23/25 Title Bausch Health nawiązuje współpracę z YUN, aby wprowadzić przełomową pielęgnację mikrobiomu skóry do Polski (Polish) Document pdf
Date 05/14/25 Title Bausch Health Announces 2025 Annual Meeting of Shareholder Results Document pdf
Date 05/06/25 Title Xifaxan® (rifaximin) Treatment Following Overt Hepatic Encephalopathy (OHE) Hospitalization Associated with Reduced Risk of 30-Day OHE Rehospitalization Document pdf
Date 04/30/25 Title Bausch Health Announces First Quarter 2025 Results Document pdf
Date 04/29/25 Title Bausch Health Announces Health Canada Clearance of Solta Medical’s Thermage® FLX System (English) Document pdf
Date 04/29/25 Title Bausch Health Announces Health Canada Clearance of Solta Medical’s Thermage® FLX System (French) Document pdf
Date 04/25/25 Title Bausch Health Announces Launch of Solta Medical’s Fraxel FTX™ Document pdf
Date 04/22/25 Title Bausch Health Announces Filing of Supplement to Proxy Statement Document pdf
Date 04/17/25 Title U.S. District Court Grants Summary Judgment in Favor of FDA, Salix, and Teva, and Against Norwich Document pdf
Date 04/14/25 Title Bausch Health Announces Adoption of Shareholder Rights Plan Document pdf
Date 04/10/25 Title Bausch Health Announces Ortho Dermatologics 2025 ASPIRE HIGHER Scholarship Program Document pdf
Date 04/02/25 Title Patient Voices Highlight the Realities of Living with Irritable Bowel Syndrome During IBS Awareness Month Document pdf
Date 03/27/25 Title Bausch Health to Announce First Quarter Results on April 30 Document pdf
Date 03/25/25 Title Bausch Health Announces Pricing of Upsized Private Offering of Senior Secured Notes Document pdf
Date 03/21/25 Title Bausch Health Announces Conditional Redemption of Senior Notes Document pdf
Date 03/19/25 Title Bausch Health Announces Launch of Private Offering of Senior Secured Notes and Conditional Redemption of Senior Notes Document pdf
Date 03/19/25 Title Bausch Health Announces Launch of Syndication of New Senior Secured Credit Facilities Document pdf
Date 03/14/25 Title Bausch Health Announces Next Steps in Financing Initiative with J.P. Morgan Document pdf
Date 02/19/25 Title Bausch Health Announces Fourth Quarter and Full Year 2024 Results Document pdf
Date 02/14/25 Title Bausch Health to Participate in the J.P. Morgan Global Leveraged Finance Conference Document pdf
Date 02/10/25 Title Bausch Health Announces 2025 Salix Gastrointestinal Health Scholars Program Document pdf
Date 02/06/25 Title Bausch Health Provides Update on Strategic Alternatives Document pdf
Date 01/23/25 Title Bausch Health to Announce Fourth Quarter and Full Year 2024 Results on February 19, 2025 Document pdf
Date 01/17/25 Title Bausch Health Statement on Selection of XIFAXAN® (rifaximin) for Inflation Reduction Act’s Medicare Negotiation Program Document pdf